Skip to main content
SpringerLink
Log in

Controlled Ovarian Stimulation for Follicular Recruitment and Oocyte Recovery in IVF

  • Chapter
Screening the Single Euploid Embryo

  • 623 Accesses

Abstract

The ultimate aim of controlled ovarian stimulation (COS) is to facilitate maximal success with minimal side effects. Multiple pregnancies with resultant maternal, fetal, and neonatal complications are an avoidable adverse outcome following IVF. This iatrogenic complication could be avoided by adopting single embryo transfer. Fine-tuning COS can lead to optimal response in terms of oocyte quantity and quality which in turn influence the subsequent events of IVF, leading to good quality embryos thus enabling selection of the single best embryo for transfer. The various events of COS including pituitary suppression, ovarian stimulation, and ovulation triggering are discussed in this chapter. The alternative approaches to each of the events are described and the concept of individualisation of COS for IVF is discussed, detailing ideal regimens for women categorised as normal responders, poor responders, or hyper-responders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Human fertilisation and embryology authority. http://www.hfea.gov.uk/5874.html. Accessed 19 May 2014.

  2. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26:1768–74.

    Article  PubMed  Google Scholar 

  3. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685–718.

    Article  CAS  PubMed  Google Scholar 

  4. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, Eijkemans MJ, Mol BW, Broekmans FJ, IMPORT Study Group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19:26–36.

    Article  PubMed  Google Scholar 

  5. Broer S, Madeleine D, Disseldorp J, Broeze KA, Opmeer BC, Patrick MM, Bossuyt P, Eijkemans MJC, Mol BW, Broekmans FJM, on behalf of the IPD-EXPORT Study Group. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril. 2013;100:420–9.

    Article  PubMed  Google Scholar 

  6. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, ESHRE Working Group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616–24.

    Article  CAS  PubMed  Google Scholar 

  7. Ng EH, Tang OS, Ho PC. The significance of the number of antral follicles prior to stimulation in predicting ovarian responses in an IVF programme. Hum Reprod. 2000;15:1937–42.

    Article  CAS  PubMed  Google Scholar 

  8. Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Muellerian hormone versus small Antral follicle count (2–6 mm). J Assist Reprod Genet. 2009;26:319–25.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013;99:1644–53.

    Article  CAS  PubMed  Google Scholar 

  10. Polyzos NP, Tournaye H, Guzman L, Camus M, Nelson SM. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2013;100:438–44.

    Article  CAS  PubMed  Google Scholar 

  11. Hughes EG, Fedorkow DM, Daya S. The routine use of gonadotropin releasing hormone agonists prior to in-vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 1992;58:888–96.

    CAS  PubMed  Google Scholar 

  12. Klingmüller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9:788–91.

    PubMed  Google Scholar 

  13. IVF Worldwide Survey. The use of GnRH agonist in IVF protocols. 2010. www.IVF-Worldwide.com. Accessed 30 May 2014.

  14. Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM, Cerotide Multiple Dose International Study Group, Cetrotide Single Dose International Study Group. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online. 2003;6:432–8.

    Article  CAS  PubMed  Google Scholar 

  15. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002;17:874–85.

    Article  CAS  PubMed  Google Scholar 

  16. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011:CD001750.

    Google Scholar 

  17. Maheshwari A, Gibreel A, Siristatidis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev. 2011:CD006919.

    Google Scholar 

  18. IVF Worldwide Survey. Poor responders: how to define, diagnose and treat? 2010. www.IVF-Worldwide.com. Accessed 30 May 2014.

  19. Sunkara SK, Coomarasamy A, Faris R, Braude P, Khalaf Y. Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Fertil Steril. 2014;101:147–53.

    Article  CAS  PubMed  Google Scholar 

  20. IVF Worldwide Survey. PCOS – definition, diagnosis and treatment. 2010. www.IVF-Worldwide.com. Accessed 30 May 2014.

  21. Lin H, Li Y, Li L, Wang W, Yang D, Zhang Q. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. PLoS One. 2014;9, e91796.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev. 1997;18:71–106.

    CAS  PubMed  Google Scholar 

  23. Fleming R, Deshpande N, Traynor I, Yates RW. Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod. 2006;21:1436–41.

    Article  CAS  PubMed  Google Scholar 

  24. Yong PY, Brett S, Baird DT, Thong KJ. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil Steril. 2003;79:308–15.

    Article  PubMed  Google Scholar 

  25. Jayaprakasan K, Hopkisson J, Campbell B, Johnson I, Thornton J, Raine-Fenning N. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. BJOG. 2010;117:853–62.

    Article  CAS  PubMed  Google Scholar 

  26. Berkkanoglu M, Ozgur K. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? Fertil Steril. 2010;94:662–5.

    Article  CAS  PubMed  Google Scholar 

  27. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113–30.

    Article  PubMed  Google Scholar 

  28. Nelson SM, Yates RW, Fleming R. Serum anti-Muellerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod. 2007;22:2414–21.

    Article  CAS  PubMed  Google Scholar 

  29. Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning Jr RV. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod. 1994;9:792–9.

    CAS  PubMed  Google Scholar 

  30. Verwoerd GR, Mathews T, Brinsden PR. Optimal follicle and oocyte numbers for cryopreservation of all embryos in IVF cycles at risk of OHSS. Reprod Biomed Online. 2008;17:312–7.

    Article  PubMed  Google Scholar 

  31. Lee KH, Kim SH, Jee BC, Kim YJ, Suh CS, Kim KC, Lee WD. Comparison of clinical characteristics between early and late patterns in hospitalized patients with ovarian hyperstimulation syndrome. Fertil Steril. 2010;93:2274–80.

    Article  CAS  PubMed  Google Scholar 

  32. Seibel MM, McArdle C, Smith D, Taymor ML. Ovulation induction in polycystic ovary syndrome with urinary follicle-stimulating hormone or human menopausal gonadotropin. Fertil Steril. 1985;43:703–8.

    CAS  PubMed  Google Scholar 

  33. Shoham Z, Insler V. Recombinant technique and gonadotropins production: new era in reproductive medicine. Fertil Steril. 1996;66:187–201.

    CAS  PubMed  Google Scholar 

  34. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011:CD005354.

    Google Scholar 

  35. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014;20:124–40.

    Article  PubMed  Google Scholar 

  36. Wide L, Eriksson K, Sluss PM, Hall JE. The common genetic variant of luteinizing hormone has a longer serum half-life than the wild type in heterozygous women. J Clin Endocrinol Metab. 2010;95:383–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Youssef MA, Al-Inany HG, Aboulghar M, Mansour R, Abou-Setta AM. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev. 2011:CD003719.

    Google Scholar 

  38. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990;71:918–22.

    Article  CAS  PubMed  Google Scholar 

  39. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril. 1991;56:213–20.

    CAS  PubMed  Google Scholar 

  40. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, Aboulfoutouh I, Khattab SM, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011:CD008046.

    Google Scholar 

  41. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2010;93:847–54.

    Article  CAS  PubMed  Google Scholar 

  42. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89:84–91.

    Article  CAS  PubMed  Google Scholar 

  43. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online. 2006;13:173–8.

    Article  CAS  PubMed  Google Scholar 

  44. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Thomas S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril. 2008;90:231–3.

    Article  CAS  PubMed  Google Scholar 

  45. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril. 2011;95:1174–7.

    Article  CAS  PubMed  Google Scholar 

  46. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006;21:1894–900.

    Article  CAS  PubMed  Google Scholar 

  47. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod. 2013;28:2511–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The author declares no conflict of interest.

Author information

Authors and Affiliations

  1. Aberdeen Fertility Centre, Aberdeen Maternity Hospital, University of Aberdeen, Aberdeen, UK

    Sesh K. Sunkara

Authors
  1. Sesh K. Sunkara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sesh K. Sunkara .

Editor information

Editors and Affiliations

  1. Center for Advanced Genetics, Reproductive Research Section, Carlsbad, California, USA

    E Scott Sills

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sunkara, S.K. (2015). Controlled Ovarian Stimulation for Follicular Recruitment and Oocyte Recovery in IVF. In: Sills, E. (eds) Screening the Single Euploid Embryo. Springer, Cham. https://doi.org/10.1007/978-3-319-16892-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16892-0_3

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16891-3

  • Online ISBN: 978-3-319-16892-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation